Erwin F. Strasser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Erwin F. Strasser has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
Reinhold Eckstein
From the Transfusion Medicine and Hemostaseology Department, University Hospital Erlangen, Erlangen, Germany
5 shared publicationsRobert Zimmermann
Department of Transfusion Medicine and Hemostaseology University Hospital of Erlangen, Friedrich‐Alexander University Erlangen‐Nürnberg (FAU) Erlangen Germany
5 shared publications- Dominik R. Weiss
Department of Transfusion Medicine and Haemostaseology, University Hospital Erlangen, Erlangen, Germany
3 shared publications - Juergen Ringwald
Department of Transfusion Medicine and Haemostaseology, University Hospital of Erlangen, Erlangen, Germany
3 shared publications - Reinhold Eckstein
Department of Transfusion Medicine and Hemostaseology
3 shared publications - Robert Zimmermann
Department of Transfusion Medicine and Hemostaseology
3 shared publications
Latest Publications
- Open Access
- 27 June 2025
- Published by Springer Nature in European Journal of Trauma and Emergency Surgery
- Vol. 51 (1) , 1-26
Inhospital coagulation management and fluid replacement therapy in patients with multiple and/or severe injuries – a systematic review and clinical practice guideline update
Purpose: Our aim was to update the evidence-based and consensus-based recommendations for inhospital coagulation management and fluid replacement therapy in patients with multiple and/or severe injuries on the basis of current evidence. This guideline topic is part of the 2022 update of the German Guideline on the Treatment of Patients with Multiple and/or Severe Injuries. Methods: MEDLINE and Embase were systematically searched to May 2021. Further literature reports were obtained from clinical experts. Randomised controlled trials, prospective cohort studies, and comparative registry studies were included if they compared interventions for the prevention of acidaemia, hypocalcaemia and hypothermia, for coagulation management, fluid replacement therapy, blood product transfusions, viscoelastic assays, or central venous access in patients with multiple and/or severe injuries in the hospital setting. We considered patient-relevant clinical outcomes, such as mortality and bleeding control, or coagulation parameters as surrogate outcomes. Risk of bias was assessed using NICE 2012 checklists. The evidence was synthesised narratively, and expert consensus was used to develop recommendations and determine their strength. Results: Fifty-nine new studies were identified. Interventions covered were blood products ( n = 19 studies), coagulation management ( n = 14), viscoelastic assays ( n = 12), temperature management ( n = 5), fluid replacement therapy ( n = 4), base excess/lactate ( n = 3), calcium ( n = 1), and intravenous access ( n = 1). Twelve recommendations were modified, and seven additional recommendations were developed. All achieved strong consensus. Conclusion: The key recommendations are summarised as follows. Trauma-induced coagulopathy (TIC) is a distinct clinical entity requiring early diagnostic and therapeutic interventions. Perform viscoelastic assays in order to aid in the diagnosis and treatment of TIC in severely bleeding trauma patients. Since only approximately 20% of trauma patients are hyperfibrinolytic and tranexamic acid is not beneficial in the absence of hyperfibrinolysis, TXA should not be indiscriminately used in all patients in the emergency department. Coagulation factor concentrates as well as TXA are indicated in patients with life-threatening haemorrhage and/or haemorrhagic shock.
- 27 June 2025
- Published by Springer Nature in European Journal of Trauma and Emergency Surgery
- Vol. 51 (1) , 1-26
Open AccessInhospital coagulation management and fluid replacement therapy in patients with multiple and/or severe injuries – a systematic review and clinical practice guideline update
Purpose: Our aim was to update the evidence-based and consensus-based recommendations for inhospital coagulation management and fluid replacement therapy in patients with multiple and/or severe injuries on the basis of current evidence. This guideline topic is part of the 2022 update of the German Guideline on the Treatment of Patients with Multiple and/or Severe Injuries. Methods: MEDLINE and Embase were systematically searched to May 2021. Further literature reports were obtained from clinical experts. Randomised controlled trials, prospective cohort studies, and comparative registry studies were included if they compared interventions for the prevention of acidaemia, hypocalcaemia and hypothermia, for coagulation management, fluid replacement therapy, blood product transfusions, viscoelastic assays, or central venous access in patients with multiple and/or severe injuries in the hospital setting. We considered patient-relevant clinical outcomes, such as mortality and bleeding control, or coagulation parameters as surrogate outcomes. Risk of bias was assessed using NICE 2012 checklists. The evidence was synthesised narratively, and expert consensus was used to develop recommendations and determine their strength. Results: Fifty-nine new studies were identified. Interventions covered were blood products ( n = 19 studies), coagulation management ( n = 14), viscoelastic assays ( n = 12), temperature management ( n = 5), fluid replacement therapy ( n = 4), base excess/lactate ( n = 3), calcium ( n = 1), and intravenous access ( n = 1). Twelve recommendations were modified, and seven additional recommendations were developed. All achieved strong consensus. Conclusion: The key recommendations are summarised as follows. Trauma-induced coagulopathy (TIC) is a distinct clinical entity requiring early diagnostic and therapeutic interventions. Perform viscoelastic assays in order to aid in the diagnosis and treatment of TIC in severely bleeding trauma patients. Since only approximately 20% of trauma patients are hyperfibrinolytic and tranexamic acid is not beneficial in the absence of hyperfibrinolysis, TXA should not be indiscriminately used in all patients in the emergency department. Coagulation factor concentrates as well as TXA are indicated in patients with life-threatening haemorrhage and/or haemorrhagic shock.
- Open Access
- 30 October 2020
- Published by Wiley in Transfusion
- Vol. 61 (2) , 368-374
Validation of a SARS‐CoV‐2 RNA RT‐PCR assay for high‐throughput testing in blood of COVID‐19 convalescent plasma donors and patients
Background: The frequency of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) RNAemia in blood donors is uncertain. Thus, assays for SARS‐CoV‐2 RNA detection in blood, validated on commercially available polymerase chain reaction (PCR) systems, are required to allow a good comparability of data.Study Design and Methods: The cobas SARS‐CoV‐2 dual‐target reverse transcriptase PCR (RT‐PCR) assay, licensed for respiratory swab SARS‐CoV‐2 RNA testing, was validated for detection of viral RNA in blood. For the validation panel, SARS‐CoV‐2–positive plasma samples were prepared by spiking SARS‐CoV‐2–positive respiratory specimens in negative human plasma. The 95% limit of detection (LOD95) was determined by probit analysis. For clinical validation, coronavirus disease 2019 (COVID‐19) convalescent plasma (CCP) donors and patients with COVID‐19 with a severe disease course treated in an intensive care unit (ICU) were included.Results: The validation of the SARS‐CoV‐2 RT‐PCR assay for blood demonstrated high sensitivity and specificity and intra‐ and inter‐assay precision and efficiency. The LOD95 for SARS‐CoV‐2 RNA was 5.0 genome copies/mL (95% confidence interval [CI], 3.3‐12 copies/mL) for target 1 and 4.3 genome copies/mL (95% CI, 2.9‐10 copies/mL) for target 2. In a cohort of 39 CCP donors with 66 CCP donations no SARS‐CoV‐2 RNA in plasma was detected. Screening of 25 blood samples of 19 ICU patients with COVID‐19 showed six positive results for SARS‐CoV‐2 RNA in at least one target of the assay.Conclusion: The SARS‐CoV‐2 RNA assay, only licensed for respiratory swabs, performed on a PCR system for high‐throughput testing, showed a good assay performance for blood testing.
- 30 October 2020
- Published by Wiley in Transfusion
- Vol. 61 (2) , 368-374
Open AccessValidation of a SARS‐CoV‐2 RNA RT‐PCR assay for high‐throughput testing in blood of COVID‐19 convalescent plasma donors and patients
Background: The frequency of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) RNAemia in blood donors is uncertain. Thus, assays for SARS‐CoV‐2 RNA detection in blood, validated on commercially available polymerase chain reaction (PCR) systems, are required to allow a good comparability of data.Study Design and Methods: The cobas SARS‐CoV‐2 dual‐target reverse transcriptase PCR (RT‐PCR) assay, licensed for respiratory swab SARS‐CoV‐2 RNA testing, was validated for detection of viral RNA in blood. For the validation panel, SARS‐CoV‐2–positive plasma samples were prepared by spiking SARS‐CoV‐2–positive respiratory specimens in negative human plasma. The 95% limit of detection (LOD95) was determined by probit analysis. For clinical validation, coronavirus disease 2019 (COVID‐19) convalescent plasma (CCP) donors and patients with COVID‐19 with a severe disease course treated in an intensive care unit (ICU) were included.Results: The validation of the SARS‐CoV‐2 RT‐PCR assay for blood demonstrated high sensitivity and specificity and intra‐ and inter‐assay precision and efficiency. The LOD95 for SARS‐CoV‐2 RNA was 5.0 genome copies/mL (95% confidence interval [CI], 3.3‐12 copies/mL) for target 1 and 4.3 genome copies/mL (95% CI, 2.9‐10 copies/mL) for target 2. In a cohort of 39 CCP donors with 66 CCP donations no SARS‐CoV‐2 RNA in plasma was detected. Screening of 25 blood samples of 19 ICU patients with COVID‐19 showed six positive results for SARS‐CoV‐2 RNA in at least one target of the assay.Conclusion: The SARS‐CoV‐2 RNA assay, only licensed for respiratory swabs, performed on a PCR system for high‐throughput testing, showed a good assay performance for blood testing.
- 1 January 2020
- Published by Clinical Laboratory Publications in Clinical Laboratory
- Vol. 66 (06/2020) , 979-989
Thrombin Generation in Fresh and Frozen-Thawed Platelet Poor Plasma - Is there a Difference?
Background: Applicability of thrombin generation tests to clinical routine has been sought for many years. The aim of this study was to compare thrombin generation measured in fresh platelet poor plasma (f-PPP) and frozen-thawed platelet poor plasma (ft-PPP) to prove the consistency of results. Methods: In this prospective study, thrombin generation was measured in twenty-fold repetitions in 3.2% citrate PPP obtained from male healthy blood donors aged 19 - 39 years (n = 54 donations). The tests were performed with fresh PPP and repeated after storing the PPP at -60 degrees C. In two subgroup analyses, the effect of higher and lower normal baseline platelet counts on the Calibrated Automated Thrombogram (CAT) assay and the influence of ABO blood groups on thrombin generation were analyzed. Results: Referring to the parameters of thrombin generation most frequently used in studies, peak thrombin of f-PPP and ft-PPP agreed in about 50% of the samples. Endogenous thrombin potential (ETP) of f-PPP and ft-PPP agreed in nearly two-thirds of the samples. A slightly but significantly slower kinetic was found in the thrombin generation of ft-PPP compared with f-PPP. At least in f-PPP, ETP correlates with baseline platelet counts of the whole blood sample. Peak thrombin was significantly higher in non-O blood groups compared to O blood group. Conclusions: A low level of agreement between the results of f-PPP and ft-PPP is shown. In terms of practicability of sample collection using semi-automated thrombin-generation assays ft-PPP should be preferred over f-PPP. We therefore recommend using ft-PPP in clinical studies.
- 1 January 2020
- Published by Clinical Laboratory Publications in Clinical Laboratory
- Vol. 66 (06/2020) , 979-989
Thrombin Generation in Fresh and Frozen-Thawed Platelet Poor Plasma - Is there a Difference?
Background: Applicability of thrombin generation tests to clinical routine has been sought for many years. The aim of this study was to compare thrombin generation measured in fresh platelet poor plasma (f-PPP) and frozen-thawed platelet poor plasma (ft-PPP) to prove the consistency of results. Methods: In this prospective study, thrombin generation was measured in twenty-fold repetitions in 3.2% citrate PPP obtained from male healthy blood donors aged 19 - 39 years (n = 54 donations). The tests were performed with fresh PPP and repeated after storing the PPP at -60 degrees C. In two subgroup analyses, the effect of higher and lower normal baseline platelet counts on the Calibrated Automated Thrombogram (CAT) assay and the influence of ABO blood groups on thrombin generation were analyzed. Results: Referring to the parameters of thrombin generation most frequently used in studies, peak thrombin of f-PPP and ft-PPP agreed in about 50% of the samples. Endogenous thrombin potential (ETP) of f-PPP and ft-PPP agreed in nearly two-thirds of the samples. A slightly but significantly slower kinetic was found in the thrombin generation of ft-PPP compared with f-PPP. At least in f-PPP, ETP correlates with baseline platelet counts of the whole blood sample. Peak thrombin was significantly higher in non-O blood groups compared to O blood group. Conclusions: A low level of agreement between the results of f-PPP and ft-PPP is shown. In terms of practicability of sample collection using semi-automated thrombin-generation assays ft-PPP should be preferred over f-PPP. We therefore recommend using ft-PPP in clinical studies.
- 4 September 2019
- Published by S. Karger AG in Cerebrovascular Diseases
- Vol. 48 (1-2) , 17-25
Direct Oral Anticoagulant Plasma Levels for the Management of Acute Ischemic Stroke
Introduction: The management of acute ischemic stroke in patients on direct oral anticoagulants (DOACs) is challenging. However, the substance-specific plasma level could guide treatment decisions on recanalization therapies. We present a plasma-level-based protocol for emergency treatment of stroke patients on oral anticoagulants. Bleeding complications and clinical outcome for patients on DOACs are reported and compared to patients on vitamin K antagonists (VKAs). Methods: In patients with acute ischemic stroke and suspected use of DOACs within 48 h prior to hospital admission, plasma levels were measured using the calibrated Xa-activity (apixaban, edoxaban, rivaroxaban) or the Hemoclot®-assay (dabigatran). Levels 100 ng/mL excluded patients from recombinant tissue plasminogen activator use. For patients on VKAs, the cutoff was set at international normalized ratio of 1.7. Endovascular thrombectomy of a large vessel occlusion was performed independently from coagulation testing. Consecutive patients were included in an observational registry. Results: Five hundred and twenty-two patients (261 on VKAs and 261 on DOACs) were included. Thirty patients (11.5%) on VKAs and 24 (9.2%) on DOACs received thrombolysis, followed by mechanical thrombectomy in 10 and 14 patients, respectively. Seventeen patients in each group received thrombectomy only. Symptomatic intracranial hemorrhage associated with thrombolysis occurred in 1 patient on VKA (3.3%) and 1 on DOAC (4.2%; p = 0.872). The turnaround time of specific assays did not show a significant delay in comparison to standard coagulation parameters. Conclusion: DOAC plasma levels could support decisions on emergency treatment of ischemic stroke. Systemic thrombolysis below suggested thresholds appears preliminary feasible and safe without an excess in bleeding complications.
- 4 September 2019
- Published by S. Karger AG in Cerebrovascular Diseases
- Vol. 48 (1-2) , 17-25
Direct Oral Anticoagulant Plasma Levels for the Management of Acute Ischemic Stroke
Introduction: The management of acute ischemic stroke in patients on direct oral anticoagulants (DOACs) is challenging. However, the substance-specific plasma level could guide treatment decisions on recanalization therapies. We present a plasma-level-based protocol for emergency treatment of stroke patients on oral anticoagulants. Bleeding complications and clinical outcome for patients on DOACs are reported and compared to patients on vitamin K antagonists (VKAs). Methods: In patients with acute ischemic stroke and suspected use of DOACs within 48 h prior to hospital admission, plasma levels were measured using the calibrated Xa-activity (apixaban, edoxaban, rivaroxaban) or the Hemoclot®-assay (dabigatran). Levels 100 ng/mL excluded patients from recombinant tissue plasminogen activator use. For patients on VKAs, the cutoff was set at international normalized ratio of 1.7. Endovascular thrombectomy of a large vessel occlusion was performed independently from coagulation testing. Consecutive patients were included in an observational registry. Results: Five hundred and twenty-two patients (261 on VKAs and 261 on DOACs) were included. Thirty patients (11.5%) on VKAs and 24 (9.2%) on DOACs received thrombolysis, followed by mechanical thrombectomy in 10 and 14 patients, respectively. Seventeen patients in each group received thrombectomy only. Symptomatic intracranial hemorrhage associated with thrombolysis occurred in 1 patient on VKA (3.3%) and 1 on DOAC (4.2%; p = 0.872). The turnaround time of specific assays did not show a significant delay in comparison to standard coagulation parameters. Conclusion: DOAC plasma levels could support decisions on emergency treatment of ischemic stroke. Systemic thrombolysis below suggested thresholds appears preliminary feasible and safe without an excess in bleeding complications.
- Open Access
- 10 January 2019
- Published by Springer Nature in BMC Anesthesiology
- Vol. 19 (1) , 1-9
Closing the gap – detection of clinically relevant von Willebrand disease in emergency settings through an improved algorithm based on rotational Thromboelastometry
Hemorrhage and blood loss are still among the main causes of preventable death. Global hemostatic assays are useful point-of-care test (POCT) devices to rapidly detect cumulative effects of plasma factors and platelets on coagulation. Thromboelastography (TEG) and Thromboelastometry (ROTEM) are established methods in many anesthesiological departments for guided hemostatic treatment. However, von Willebrand disease remains undetected by standard ROTEM, especially during emergency care, despite being the most prevalent congenital hemostatic disorder. In our monocentric cohort pilot study we focused on hemostatic challenges associated with von Willebrand disease. Twenty-seven patients with suspected von Willebrand disease were included. We modified the routine ROTEM assay by adding a preincubation with ristocetin and commercially available plasma-derived von Willebrand factor to identify clinically relevant von Willebrand disease (VWD). Addition of von Willebrand factor to the ristocetin assay of a VWD type 3 patient restored the reaction of the whole blood probe to match the response of a healthy person. Our modified ROTEM assay with ristocetin (Ricotem) showed that all high responders (n = 7) had VWD. In the low responder group (n = 16) – 10 of 16 had VWD and in the normal responder group (n = 5), 2 of 5 had mild type 1 VWD. This new modification of the standard ROTEM assay enables the detection of otherwise unnoticed critical von Willebrand disease based on alterations in clot formation and might serve as a novel approach to reliably assess severe VWD patients by platelet-mediated blood clotting in an emergency setting. We recommend incorporating this new VWD-focused screening tool into the current ROTEM-based management algorithm of acute microvascular bleeding.
- 10 January 2019
- Published by Springer Nature in BMC Anesthesiology
- Vol. 19 (1) , 1-9
Open AccessClosing the gap – detection of clinically relevant von Willebrand disease in emergency settings through an improved algorithm based on rotational Thromboelastometry
Hemorrhage and blood loss are still among the main causes of preventable death. Global hemostatic assays are useful point-of-care test (POCT) devices to rapidly detect cumulative effects of plasma factors and platelets on coagulation. Thromboelastography (TEG) and Thromboelastometry (ROTEM) are established methods in many anesthesiological departments for guided hemostatic treatment. However, von Willebrand disease remains undetected by standard ROTEM, especially during emergency care, despite being the most prevalent congenital hemostatic disorder. In our monocentric cohort pilot study we focused on hemostatic challenges associated with von Willebrand disease. Twenty-seven patients with suspected von Willebrand disease were included. We modified the routine ROTEM assay by adding a preincubation with ristocetin and commercially available plasma-derived von Willebrand factor to identify clinically relevant von Willebrand disease (VWD). Addition of von Willebrand factor to the ristocetin assay of a VWD type 3 patient restored the reaction of the whole blood probe to match the response of a healthy person. Our modified ROTEM assay with ristocetin (Ricotem) showed that all high responders (n = 7) had VWD. In the low responder group (n = 16) – 10 of 16 had VWD and in the normal responder group (n = 5), 2 of 5 had mild type 1 VWD. This new modification of the standard ROTEM assay enables the detection of otherwise unnoticed critical von Willebrand disease based on alterations in clot formation and might serve as a novel approach to reliably assess severe VWD patients by platelet-mediated blood clotting in an emergency setting. We recommend incorporating this new VWD-focused screening tool into the current ROTEM-based management algorithm of acute microvascular bleeding.
- 1 May 2018
- Published by Springer Nature in Der Unfallchirurg
- Vol. 121 (5) , 423-428
The new hemotherapy guideline
The 2017 update of the German guidelines on hemotherapy is highly associated with the drug legislation and guidelines and thus necessitated a new structure of the contents. These guidelines reflect the state of the art for collection and application of blood and blood components corresponding to the Transfusion Act and is therefore the main document in hemotherapy. Topics of high interest in this 2017 update related to application of blood products are clarification and consent of patients, obligation for documentation, information, reporting and notification reports in the case of transfusion reactions and detailed description of quality management and quality assurance, as well as task description of persons responsible for the organization or implementation of transfusion-associated workflows. Surveillance, collating and management of errors are important prerequisites for the continuous optimization of patient safety. Patient blood management (PBM) as a requirement for the efficient use of blood products and the controlled and economical usage of autologous hemotherapy procedures (e.g. mechanical autotransfusion, MAT) are measures to reduce the need for blood products. All medical specialist societies, which carry out hemotherapy and participate in the standing committee of the Federal Medical Council (BAK) to revise the hemotherapy guidelines have to take care that the guidelines are understandable for medical doctors and the transfusion team. Additionally, the core principles of hemotherapy have to be described in a clear and distinct manner.
- 1 May 2018
- Published by Springer Nature in Der Unfallchirurg
- Vol. 121 (5) , 423-428
The new hemotherapy guideline
The 2017 update of the German guidelines on hemotherapy is highly associated with the drug legislation and guidelines and thus necessitated a new structure of the contents. These guidelines reflect the state of the art for collection and application of blood and blood components corresponding to the Transfusion Act and is therefore the main document in hemotherapy. Topics of high interest in this 2017 update related to application of blood products are clarification and consent of patients, obligation for documentation, information, reporting and notification reports in the case of transfusion reactions and detailed description of quality management and quality assurance, as well as task description of persons responsible for the organization or implementation of transfusion-associated workflows. Surveillance, collating and management of errors are important prerequisites for the continuous optimization of patient safety. Patient blood management (PBM) as a requirement for the efficient use of blood products and the controlled and economical usage of autologous hemotherapy procedures (e.g. mechanical autotransfusion, MAT) are measures to reduce the need for blood products. All medical specialist societies, which carry out hemotherapy and participate in the standing committee of the Federal Medical Council (BAK) to revise the hemotherapy guidelines have to take care that the guidelines are understandable for medical doctors and the transfusion team. Additionally, the core principles of hemotherapy have to be described in a clear and distinct manner.
- 12 July 2017
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 56 (4) , 535-538
First comparative analysis concerning the plasma platelet contamination during MNC collection
- 12 July 2017
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 56 (4) , 535-538
First comparative analysis concerning the plasma platelet contamination during MNC collection
- Open Access
- 20 April 2017
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 2 (8)
Twelve-year survival and immune correlates in dendritic cell–vaccinated melanoma patients
Background. Reports on long-term (≥10 years) effects of cancer vaccines are missing. Therefore, in 2002, we initiated a phase I/II trial in cutaneous melanoma patients to further explore the immunogenicity of our DC vaccine and to establish its long-term toxicity and clinical benefit after a planned 10-year followup. Methods. Monocyte-derived DCs matured by TNFα, IL-1β, IL-6, and PGE 2 and then loaded with 4 HLA class I and 6 class II–restricted tumor peptides were injected intradermally in high doses over 2 years. We performed serial immunomonitoring in all 53 evaluable patients. Results. Vaccine-specific immune responses including high-affinity, IFNγ-producing CD4 + and lytic polyfunctional CD8 + T cells were de novo induced or boosted in most patients. Exposure of mature DCs to trimeric soluble CD40 ligand, unexpectedly, did not further enhance such immune responses, while keyhole limpet hemocyanin (KLH) pulsing to provide unspecific CD4 + help promoted CD8 + T cell responses — notably, their longevity. An unexpected 19% of nonresectable metastatic melanoma patients are still alive after 11 years, a survival rate similar to that observed in ipilimumab-treated patients and achieved without any major (>grade 2) toxicity. Survival correlated significantly with the development of intense vaccine injection site reactions, and with blood eosinophilia after the first series of vaccinations, suggesting that prolonged survival was a consequence of DC vaccination. Conclusions. Long-term survival in advanced melanoma patients undergoing DC vaccination is similar to ipilimumab-treated patients and occurs upon induction of tumor-specific T cells, blood eosinophilia, and strong vaccine injection site reactions occurring after the initial vaccinations. TRIAL REGISTRATION. ClinicalTrials.gov NCT00053391. FUNDING. European Community, Sixth Framework Programme (Cancerimmunotherapy LSHC-CT-2006-518234; DC-THERA LSHB-CT-2004-512074), and German Research Foundation (CRC 643, C1, Z2).
- 20 April 2017
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 2 (8)
Open AccessTwelve-year survival and immune correlates in dendritic cell–vaccinated melanoma patients
Background. Reports on long-term (≥10 years) effects of cancer vaccines are missing. Therefore, in 2002, we initiated a phase I/II trial in cutaneous melanoma patients to further explore the immunogenicity of our DC vaccine and to establish its long-term toxicity and clinical benefit after a planned 10-year followup. Methods. Monocyte-derived DCs matured by TNFα, IL-1β, IL-6, and PGE 2 and then loaded with 4 HLA class I and 6 class II–restricted tumor peptides were injected intradermally in high doses over 2 years. We performed serial immunomonitoring in all 53 evaluable patients. Results. Vaccine-specific immune responses including high-affinity, IFNγ-producing CD4 + and lytic polyfunctional CD8 + T cells were de novo induced or boosted in most patients. Exposure of mature DCs to trimeric soluble CD40 ligand, unexpectedly, did not further enhance such immune responses, while keyhole limpet hemocyanin (KLH) pulsing to provide unspecific CD4 + help promoted CD8 + T cell responses — notably, their longevity. An unexpected 19% of nonresectable metastatic melanoma patients are still alive after 11 years, a survival rate similar to that observed in ipilimumab-treated patients and achieved without any major (>grade 2) toxicity. Survival correlated significantly with the development of intense vaccine injection site reactions, and with blood eosinophilia after the first series of vaccinations, suggesting that prolonged survival was a consequence of DC vaccination. Conclusions. Long-term survival in advanced melanoma patients undergoing DC vaccination is similar to ipilimumab-treated patients and occurs upon induction of tumor-specific T cells, blood eosinophilia, and strong vaccine injection site reactions occurring after the initial vaccinations. TRIAL REGISTRATION. ClinicalTrials.gov NCT00053391. FUNDING. European Community, Sixth Framework Programme (Cancerimmunotherapy LSHC-CT-2006-518234; DC-THERA LSHB-CT-2004-512074), and German Research Foundation (CRC 643, C1, Z2).
- Open Access
- 3 August 2016
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 11 (1) , 1-8
Vascular type Ehlers-Danlos syndrome is associated with platelet dysfunction and low vitamin D serum concentration
The vascular type represents a very rare, yet the clinically most fatal entity of Ehlers-Danlos syndrome (EDS). Patients are often admitted due to arterial bleedings and the friable tissue and the altered coagulation contribute to the challenge in treatment strategies. Until now there is little information about clotting characteristics that might influence hemostasis decisively and eventually worsen emergency situations. 22 vascular type EDS patients were studied for hemoglobin, platelet volume and count, Quick and activated partial thromboplastin time, fibrinogen, factor XIII, von Willebrand disease, vitamin D and platelet aggregation by modern standard laboratory methods. Results show a high prevalence of over 50 % for platelet aggregation disorders in vascular type EDS patients, especially for collagen and epinephrine induced tests, whereas the plasmatic cascade did not show any alterations. Additionally, more than half of the tested subjects showed low vitamin D serum levels, which might additionally affect vascular wall integrity. The presented data underline the importance of detailed laboratory screening methods in vascular type EDS patients in order to allow for targeted application of platelet-interacting substances that might be of decisive benefit in the emergency setting.
- 3 August 2016
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 11 (1) , 1-8
Open AccessVascular type Ehlers-Danlos syndrome is associated with platelet dysfunction and low vitamin D serum concentration
The vascular type represents a very rare, yet the clinically most fatal entity of Ehlers-Danlos syndrome (EDS). Patients are often admitted due to arterial bleedings and the friable tissue and the altered coagulation contribute to the challenge in treatment strategies. Until now there is little information about clotting characteristics that might influence hemostasis decisively and eventually worsen emergency situations. 22 vascular type EDS patients were studied for hemoglobin, platelet volume and count, Quick and activated partial thromboplastin time, fibrinogen, factor XIII, von Willebrand disease, vitamin D and platelet aggregation by modern standard laboratory methods. Results show a high prevalence of over 50 % for platelet aggregation disorders in vascular type EDS patients, especially for collagen and epinephrine induced tests, whereas the plasmatic cascade did not show any alterations. Additionally, more than half of the tested subjects showed low vitamin D serum levels, which might additionally affect vascular wall integrity. The presented data underline the importance of detailed laboratory screening methods in vascular type EDS patients in order to allow for targeted application of platelet-interacting substances that might be of decisive benefit in the emergency setting.
- 4 August 2014
- Published by Wiley in Vox Sanguinis
- Vol. 108 (1) , 89-95
Buffy coat volume reduction for optimization of leucapheresis harvests produced by the autoMNC program
- 4 August 2014
- Published by Wiley in Vox Sanguinis
- Vol. 108 (1) , 89-95
Buffy coat volume reduction for optimization of leucapheresis harvests produced by the autoMNC program